(Q45397583)

14 December 2017

title

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. (English)

1 reference

14 December 2017

1 reference

peginterferon alfa-2a

1 reference

1 reference

1 reference

9

0 references

Patrick Marcellin

4

object named as

Patrick Marcellin

1 reference

14 December 2017

Michael W Fried

1

1 reference

14 December 2017

Teerha Piratvisuth

2

1 reference

14 December 2017

George K K Lau

3

1 reference

14 December 2017

Wan-Cheng Chow

5

1 reference

14 December 2017

Graham Cooksley

6

1 reference

14 December 2017

Kang-Xian Luo

7

1 reference

14 December 2017

Seung Woon Paik

8

1 reference

14 December 2017

Peter Button

10

1 reference

14 December 2017

Matei Popescu

11

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

14 December 2017

1 reference

14 December 2017

volume

47

1 reference

14 December 2017

issue

2

1 reference

14 December 2017

page(s)

428-434

1 reference

Hepatitis B e antigen and infectivity of hepatitis B virus

14 December 2017

cites work

1 reference

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

21 January 2018

1 reference

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

7 January 2021

Treatment of chronic hepatitis B: case selection and duration of therapy

1 reference

7 January 2021

Nucleoside analogs as anti-HBV agents

1 reference

7 January 2021

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

1 reference

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

7 January 2021

Guidelines for stopping therapy in chronic hepatitis C.

1 reference

7 January 2021

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy

1 reference

7 January 2021

Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants

1 reference

7 January 2021

Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B

1 reference

7 January 2021

The use of receiver operating characteristic curves in biomedical informatics

1 reference

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

7 January 2021

Chronic hepatitis B: update of recommendations

1 reference

7 January 2021

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

1 reference

7 January 2021

Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study

1 reference

7 January 2021

Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays

1 reference

7 January 2021

Molecular diagnosis of viral hepatitis

1 reference

7 January 2021

Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C.

1 reference

7 January 2021

Chronic hepatitis B: current testing strategies.

1 reference

7 January 2021

1 reference

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

7 January 2021

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22065

1 reference

14 December 2017

1 reference